These findings are in line with the observed effects of MGMT protein expression on tumor response, suggesting that the upregulation of DDR mechanisms in SMARCB1-deficient tumors plays a role in supporting cell survival during DNA-damaging therapies. The gene discussed is SMARCB1; the disease is neoplasm.